TWC
AVDL

TD Waterhouse Canada’s Avadel Pharmaceuticals AVDL Stock Holding History

TD Waterhouse Canada’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,242
Closed -$26.8K – 2314
2025
Q4 		$26.8K Buy
+1,242
New +$24.1K ﹤0.01% 1329

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

TD Waterhouse Canada's AVDL Position: Q1 2026 in Review

TD Waterhouse Canada sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 1,242 shares — an estimated $26.8K sold.

TD Waterhouse Canada first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $26.8K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • TD Waterhouse Canada reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • TD Waterhouse Canada sold 1,242 Avadel Pharmaceuticals shares in Q1 2026, an estimated $26.8K.
  • TD Waterhouse Canada first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • TD Waterhouse Canada's Avadel Pharmaceuticals position peaked at $26.8K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.